Revium Rx

Advanced Lipid-based Platform

Health Tech & Life Sciences
Private
Follow

Company Overview

Snapshot

Founded in June 2021, Revium Rx operates with 1–10 employees. The company completed the acquisition of LipoVation Ltd. in February 2025, a strategic move to enhance its nanoparticle drug development capabilities.

Business overview

Revium Rx develops advanced delivery systems for various indications, focusing on hard-to-treat diseases by enhancing and improving encapsulated therapeutics. The company's pipeline includes antibiotics for antimicrobial-resistant bacteria, an immune checkpoint inhibitor adjuvant for solid tumors, and a novel immunization platform. Operating within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Drug Delivery, Revium Rx serves the global market with its B2B business model.

Strategic signal

Revium Rx's acquisition of LipoVation Ltd. in February 2025 signals a significant strategic expansion in its nanoparticle drug development capabilities. This move is poised to accelerate the company's efforts in tackling critical health challenges like antibiotic resistance and cancer, demonstrating a clear intent to strengthen its position in advanced drug delivery systems and broaden its therapeutic horizons.

Log in to access full profile

Company Intelligence Q&A

What is Revium Rx's core focus?
Revium Rx focuses on developing advanced delivery systems for various indications, aiming to expand therapeutic horizons for hard-to-treat diseases by enhancing encapsulated therapeutics.
What was a key strategic development for Revium Rx in early 2025?
In February 2025, Revium Rx completed the acquisition of LipoVation Ltd., a move aimed at bolstering its nanoparticle drug development capabilities.
What specific areas does Revium Rx's current pipeline address?
Revium Rx's current pipeline includes antibiotics for antimicrobial-resistant bacteria, an immune checkpoint inhibitor adjuvant for solid tumors, and a novel immunization platform.
What is the primary sector in which Revium Rx operates?
Revium Rx operates primarily in the Health Tech & Life Sciences sector, with a focus on Pharma & Medical Biotechnology and Drug Delivery.
What is the significance of Revium Rx's nanoparticle technology?
Revium Rx's nanoparticle technology, highlighted in March 2025, aims to tackle critical issues such as antibiotic resistance and other challenging medical conditions.
Log in to access full profile